GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » EV-to-EBIT

Peptron (XKRX:087010) EV-to-EBIT : -58.40 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Peptron's Enterprise Value is ₩674,584 Mil. Peptron's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-11,551 Mil. Therefore, Peptron's EV-to-EBIT for today is -58.40.

The historical rank and industry rank for Peptron's EV-to-EBIT or its related term are showing as below:

XKRX:087010' s EV-to-EBIT Range Over the Past 10 Years
Min: -331.58   Med: -38.37   Max: -6.35
Current: -58.4

During the past 10 years, the highest EV-to-EBIT of Peptron was -6.35. The lowest was -331.58. And the median was -38.37.

XKRX:087010's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs XKRX:087010: -58.40

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Peptron's Enterprise Value for the quarter that ended in Mar. 2024 was ₩583,702 Mil. Peptron's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-11,551 Mil. Peptron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.98%.


Peptron EV-to-EBIT Historical Data

The historical data trend for Peptron's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron EV-to-EBIT Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.50 -15.73 -13.63 -10.13 -53.48

Peptron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.66 -16.03 -37.36 -53.48 -50.53

Competitive Comparison of Peptron's EV-to-EBIT

For the Biotechnology subindustry, Peptron's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Peptron's EV-to-EBIT falls into.



Peptron EV-to-EBIT Calculation

Peptron's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=674584.123/-11550.984
=-58.40

Peptron's current Enterprise Value is ₩674,584 Mil.
Peptron's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-11,551 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peptron  (XKRX:087010) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Peptron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-11550.984/583702.36
=-1.98 %

Peptron's Enterprise Value for the quarter that ended in Mar. 2024 was ₩583,702 Mil.
Peptron's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-11,551 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peptron EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Peptron's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron (XKRX:087010) Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines